Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:41 AM
Ignite Modification Date:
2025-12-25 @ 2:41 AM
NCT ID:
NCT06495333
Brief Summary:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of liver weight not explained by at-risk alcohol intake. Risk factors include obesity, diabetes, genetic variants, dietary factors, and gut microbiota alterations. However, the interdependence of these factors and their individual impact on disease severity remain unclear. The investigators aim to investigate the changes in the gut microbiome of Hispanics living in Puerto Rico with MASLD associated with wild-type and mutated genotype status of PNPLA3 rs738409, a strong genetic contributor to MASLD. In this cross-sectional study, blood and fecal samples will be collected from participants who have completed a non-invasive transient elastography test (FibroScan) to measure the extent of hepatic steatosis (fat in the liver). Genotyping for the PNPLA3 rs738409 variant will be conducted. Fecal samples will be collected to analyze the V4 region of the 16S rRNA gene for intestinal microbiota characterization. Alpha and beta diversity analysis will be measured by MASLD status and PNPLA3 genotype to evaluate biodiversity within and between samples.
Detailed Description:
The liver is the powerhouse of the body, overseeing many functions such as the production of clotting factors, sugars, fats, and the metabolism of drugs. MASLD is the most common chronic liver disease worldwide, affecting one in three adults and one in ten children. MASLD, more commonly referred to as "fatty liver," can lead to fat accumulation in liver cells or steatosis and is strongly associated with obesity and diabetes. The disease is usually considered a silent condition with few symptoms until advanced liver disease or cirrhosis develops. Fortunately, fatty liver may be reversed by adopting a healthy lifestyle, including weight loss and exercise. However, the pathogenesis of MASLD remains incompletely understood, and the Hispanic subpopulation is affected the most.
A multi-hit model has been proposed that most accurately describes both the development of simple steatosis and its transition from simple steatosis to progressive stages of the disease. In this model, a close interaction between dietary, environmental, and genetic factors with insulin resistance, lipotoxicity, and fat metabolism comprises multiple insults acting together on predisposed subjects to induce MASLD. This model has led to the understanding that the interplay between diet, genetics, and gut microbiota is of utmost importance in the development and progression of the condition. As a multi-factorial disease, assigning specific disease pathways to the overall phenotype has been challenging. Still, it is important to investigate associations between its risk factors to direct therapeutic interventions to the most relevant pathways.
Looking at two of the most relevant risk factors, this study aims to investigate whether there are any differences in the taxonomic composition of the gut microbiota between Hispanic patients with MASLD with different PNPLA3 genotypes. The PNPLA3 (patatin-like phospholipase domain-containing protein 3) polymorphism has been implicated in the pathogenesis and progression of the condition. However, the role of PNPLA3 polymorphism in shaping the fecal microbiota composition in Hispanic patients with MASLD remains unclear. Once fecal and blood samples are collected from a cohort of Hispanic individuals with MASLD, fecal microbiota sequencing and PNPLA3 genotyping will be done. Findings will reveal whether there are significant alterations in the fecal microbiota composition in relation to PNPLA3 polymorphism in Hispanic patients with MASLD. Results could provide evidence for a potential link between PNPLA3 polymorphism and fecal microbiota composition in Hispanic individuals with MASLD.
Study:
NCT06495333
Study Brief:
Protocol Section:
NCT06495333